Today we’re going to revisit a guest whose mission is to increase the GDP of not a country, but the internet.

If it rings a bell, yes, we are indeed talking about Stripe, the payments processing company whose aim is to build the economic infrastructure for the internet.

For starters, the San Francisco and Dublin headquartered firm assists customers from the world’s largest enterprises to budding startups in accepting payments, growing their revenue and tapping new business opportunities.

More specifically, its service offerings cut across functions such as pricing, billing, checkouts, payment links, revenue recognition to invoicing and marketplace solutions.

We are speaking to Stripe once again because a lot has happened since our last interview with the company in 2024.

Per the firm’s latest annual letter, Stripe reached a valuation of a whopping US$159 billion as of 2026, climbing up from US$106.7 billion achieved in September 2025. So what are the key drivers of growth bolstering the numbers?

Also – how is the firm preparing for a world enabled by artificial intelligence, with technologies such as agentic commerce set to shake up the online shopping landscape?

Meanwhile, Stripe is also big on stablecoins, having in February 2025 acquired stablecoin orchestration platform Bridge for US$1.1 billion. But how has the firm tapped on the speed and cost advantages of stablecoins in its business thus far?

On Under the Radar, Money Matters’ finance presenter Chua Tian Tian posed these questions to Paul Harapin, Chief Revenue Officer, Asia Pacific & Japan, Stripe.

See omnystudio.com/listener for privacy information.

As the largest aeronautics and space company in Europe, Airbus provides products, services and solutions for the commercial aircraft, helicopter, defence and space sectors.

They range from the commercial aircraft and helicopters that connect people from around the world to military aircraft and satellites that aim to protect citizens and countries.

Its 12,000-plus Airbus aircrafts in service collectively serve over 48,000 routes globally, closing the distance between people every day.

In February 2026, the firm reported net orders of 889 commercial aircrafts after cancellations in 2025, higher than the 826 seen in 2024, while the order backlog amounted to a year-end record of 8,754 commercial aircrafts at the end of 2025.

But how much of this is contributed by Asia Pacific, and how does the company assess the speed at which it is delivering to customers in the region amid shortages in Pratt & Whitney engines?

Also – how does it assess competition from up and coming players in the region, say China’s state-owned planemaker Comac?

Meanwhile, Airbus has said that Asia Pacific will need almost 20,000 new aircrafts as it is set to remain as the world’s fastest-growing air travel market.

But what are the key trends supporting the numbers, and how is Airbus working to capture and realise demand from the region?

In this “On the Go” Special episode of Under the Radar, Money Matters’ finance presenter Chua Tian Tian headed down to the Airbus Campus at Seletar Aerospace Park, where she posed the questions to Anand Stanley, President, Airbus Asia-Pacific.

See omnystudio.com/listener for privacy information.

Today we’re going to take you through the company behind the GLP-1 drugs Wegovy and Ozempic that are used to treat obesity and diabetes.

Founded in 1923 and headquartered just outside Copenhagen in Denmark, Novo Nordisk prides itself as a global healthcare company that aims to drive change to defeat serious chronic disease and build on its heritage in diabetes.

The Danish drugmaker said it seeks to do so by pioneering scientific breakthroughs, expanding access to its medicines and working to prevent and ultimately cure the diseases it treats.

Fast forward to today, Novo Nordisk’s global footprint spans across 170 countries, with production facilities in 13 of them, and 10 research and development centres in key markets China, Denmark, India, the UK and the US.

Novo Nordisk is a company to watch because of its breakthrough GLP-1 injectable medications for diabetes and obesity care in recent years. But what are the key drivers of growth for the firm right now?

Meanwhile, concerns surrounding competition against other industry peers such as Eli Lilly continue to weigh on investors’ minds as they mull what the next battleground for the big pharmaceutical players will be.

That’s especially so with the expiry of the firm’s patents in key markets nearing.

But it seems like oral pills are the next chapter for pharmaceutical firms targeting the obesity market, with Novo Nordisk rolling out its first GLP-1 pill for weight loss in the US earlier in January.

With Goldman Sachs in 2025 forecasting the daily oral pills will capture about a quarter of the anti-obesity medication market by 2030, how will Novo Nordisk’s oral GLP-1 medications augment its growth trajectory?

On Under the Radar, Money Matters’ finance presenter Chua Tian Tian posed these questions to Jay Thyagarajan, Senior Vice President, Region APAC, Novo Nordisk.

See omnystudio.com/listener for privacy information.